Patents by Inventor Antonius J. H. Stegmann
Antonius J. H. Stegmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8361478Abstract: Described are vaccines against malarial infections, which are based on recombinant viral vectors, such as alpha viruses, adenoviruses, or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Codon-optimized circumsporozoite genes are disclosed. Replication-defective adenoviruses may be used, derived from serotypes that encounter low titers of neutralizing antibodies. Also described is the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.Type: GrantFiled: November 8, 2011Date of Patent: January 29, 2013Assignee: Crucell Holland B.V.Inventors: Maria G. Pau, Lennart Holterman, Jorn Kaspers, Antonius J. H. Stegmann
-
Publication number: 20120082694Abstract: Described are vaccines against malarial infections, which are based on recombinant viral vectors, such as alpha viruses, adenoviruses, or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Codon-optimized circumsporozoite genes are disclosed. Replication-defective adenoviruses may be used, derived from serotypes that encounter low titers of neutralizing antibodies. Also described is the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.Type: ApplicationFiled: November 8, 2011Publication date: April 5, 2012Inventors: Maria G. Pau, Lennart Holterman, Jorn Kaspers, Antonius J. H. Stegmann
-
Patent number: 8097453Abstract: Described are vaccines against malarial infections, which are based on recombinant viral vectors, such as alpha viruses, adenoviruses, or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Codon-optimized circumsporozoite genes are disclosed. Replication-defective adenoviruses may be used, derived from serotypes that encounter low titers of neutralizing antibodies. Also described is the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.Type: GrantFiled: December 1, 2010Date of Patent: January 17, 2012Assignee: Crucell Holland B.V.Inventors: Maria G. Pau, Lennart Holterman, Jorn Kaspers, Antonius J. H. Stegmann
-
Publication number: 20110150930Abstract: Described are vaccines against malarial infections, which are based on recombinant viral vectors, such as alpha viruses, adenoviruses, or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Codon-optimized circumsporozoite genes are disclosed. Replication-defective adenoviruses may be used, derived from serotypes that encounter low titers of neutralizing antibodies. Also described is the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.Type: ApplicationFiled: December 1, 2010Publication date: June 23, 2011Applicant: Crucell Holland B.V.Inventors: Maria G. Pau, Lennart Holterman, Jorn Kaspers, Antonius J. H. Stegmann
-
Patent number: 7867764Abstract: The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are disclosed. Preferably, replication-defective adenoviruses are used, derived from serotypes that encounter low titers of neutralizing antibodies. The invention, therefore, also relates to the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.Type: GrantFiled: October 18, 2007Date of Patent: January 11, 2011Assignee: Crucell Holland B.V.Inventors: Maria G. Pau, Lennart Holterman, Jorn Kaspers, Antonius J. H. Stegmann
-
Publication number: 20100172928Abstract: The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are disclosed. Preferably, replication-defective adenoviruses are used, derived from serotypes that encounter low titers of neutralizing antibodies. The invention, therefore, also relates to the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.Type: ApplicationFiled: October 18, 2007Publication date: July 8, 2010Applicant: Crucell Holland B.V.Inventors: Maria G. Pau, Lennart Holterman, Jorn Kaspers, Antonius J. H. Stegmann
-
Patent number: 7524947Abstract: The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are disclosed. Preferably, replication-defective adenoviruses are used, derived from serotypes that encounter low titers of neutralizing antibodies. The invention, therefore, also relates to the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.Type: GrantFiled: December 1, 2006Date of Patent: April 28, 2009Assignee: Crucell Holland B.V.Inventors: Maria G. Pau, Lennart Holterman, Jorn Kaspers, Antonius J. H. Stegmann
-
Patent number: 7521229Abstract: The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are disclosed. Preferably, replication-defective adenoviruses are used, derived from serotypes that encounter low titers of neutralizing antibodies. The invention, therefore, also relates to the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.Type: GrantFiled: October 18, 2007Date of Patent: April 21, 2009Assignee: Crucell Holland B.V.Inventors: Maria G. Pau, Lennart Holterman, Jorn Kaspers, Antonius J. H. Stegmann
-
Patent number: 7491395Abstract: The present invention provides methods and means for preparing vaccines that are capable of eliciting strong immune responses, especially through intranasal delivery. The invention discloses particles, referred to as “co-micelles,” in which antigens are present that interact through hydrophobic interactions with certain specific types of amphiphilic compounds, wherein the amphiphilic compounds have adjuvant activity and wherein the antigens are preferably antigenic surface proteins, such as integral membrane proteins from infectious agents like viruses.Type: GrantFiled: May 13, 2005Date of Patent: February 17, 2009Assignee: Bestewil Holding B.V.Inventor: Antonius J. H. Stegmann
-
Publication number: 20080220014Abstract: The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are disclosed. Preferably, replication-defective adenoviruses are used, derived from serotypes that encounter low titers of neutralizing antibodies. The invention, therefore, also relates to the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.Type: ApplicationFiled: October 18, 2007Publication date: September 11, 2008Applicant: Crucell Holland B.V.Inventors: Maria G. Pau, Lennart Holterman, Jorn Kaspers, Antonius J. H. Stegmann
-
Patent number: 7387894Abstract: The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are disclosed. Preferably, replication-defective adenoviruses are used, derived from serotypes that encounter low titers of neutralizing antibodies. The invention, therefore, also relates to the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.Type: GrantFiled: December 1, 2006Date of Patent: June 17, 2008Assignee: Crucell Holland B.V.Inventors: Maria G. Pau, Lennart Holterman, Jorn Kaspers, Antonius J. H. Stegmann
-
Patent number: 7300657Abstract: The present invention relates to novel vaccines against malaria infections, based on recombinant viral vectors, such as alpha viruses, adenoviruses or vaccinia viruses. The recombinant viral-based vaccines can be used to immunize against different Plasmodium infections, such as infections by P. falciparum or P. yoelii. Novel codon-optimized circumsporozoite genes are disclosed. Preferably, replication-defective adenoviruses are used, derived from serotypes that encounter low titers of neutralizing antibodies. The invention, therefore, also relates to the use of different adenoviral serotypes that are administered to elicit a strong immune response, either in single vaccination set-ups or in prime-boost set-ups in which compositions based on different serotypes can be applied.Type: GrantFiled: June 2, 2005Date of Patent: November 27, 2007Assignee: Crucell Holland B.V.Inventors: Maria G. Pau, Lennart Holterman, Jorn Kaspers, Antonius J. H. Stegmann